Shahram Teimourian

Iran University of Medical Sciences, Iran

Title: Thwarting PTEN expression by siRNA, augments HL-60 cell differentiation to neutrophillike cells by DMSO and ATRA and reduces NETosis


Shaharm Teimourian has completed his PhD at the age of 32 years from Tehran University and postdoctoral studies from Oxford University School of Medicine. He is the Director of medical genetics and biotechnology department. He has published more than 25 papers in reputed journals and has been serving as an Editorial board member of Edorium journal of molecular biology and world journal of hematology.


Abnormal cell differentiation,in particular suppression of terminal cell differentiation, exits in all tumors. Therapeutic interventions to restore terminal differentiation (“differentiation therapy”) are a very attractive way to treat cancer, especially leukemia.A variety of chemicals stimulates differentiation of leukemic cells, such as dimethyl sulfoxide (DMSO) and all-trans retinoic acid (ATRA). Tumor suppressor geneshave a vital role in thegateway to terminal cell differentiation.

In this study we inhibited PTENtumor suppressor gene expression by siRNA to investigate the effect of potentiating cell survival and inhibiting apoptosis on HL-60 cell differentiation by DMSO and ATRA at the same time we looked at Netosis.

Our results show that PTEN siRNA increasesHL-60 cell differentiation in the presence of DMSO and ATRA. At the same time the presence of siRNA hampered accumulation of apoptotic cells during incubation. PTEN siRNA reduced Net formation by differentiated neutrophils

Conclusion: Our study suggests potential usage of differentiation therapy in PTEN mutated AML leukemia.